|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01181388 |
|
Date of registration:
|
11/08/2010 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
SUIT-AMI |
|
Scientific title:
|
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients |
|
Date of first enrolment:
|
April 2010 |
|
Target sample size:
|
200 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01181388 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Shaoping Shaoping, MD. PhD |
|
Address:
|
|
|
Telephone:
|
+861064456995 |
|
Email:
|
wang_shaoping@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Shaoping Wang, MD, PhD |
|
Address:
|
|
|
Telephone:
|
+861064456995 |
|
Email:
|
wang_shaoping@hotmail.com |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- STEMI patients
- chest pain for less than 12hr
- plan to PCI
Exclusion Criteria:
- LM lesion
- stent thrombosis
- cardiac shock
- thrombocytopenia
- allergy to asprin
Age minimum:
18 Years
Age maximum:
75 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Myocardial Infarction
|
|
Intervention(s)
|
|
Procedure: administration of tirofiban by guide catheter
|
|
Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
|
|
Primary Outcome(s)
|
|
Major adverse cardiovascular events
[Time Frame: 3 months after PCI]
|
|
Major Adverse Cardiovascular Events
[Time Frame: 6 months after PCI]
|
|
Major adverse cardiovascular events
[Time Frame: 1 month after PCI]
|
|
Secondary Outcome(s)
|
|
number of participants with bleeding events
[Time Frame: 1 month]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|